ACHL - achillestx.com Company Cash Volume

Corporate emblem and logo of Achilles Therapeutics (ACHL)

Achilles Therapeutics (ACHL) attracts leading immunologists through a robust scientific foundation and stock options, which impacts its financial profile. The cash balance demonstrates current liquidity, with the metric standing at 0.09. The company is implementing automated bioreactors to eliminate errors during cell cultivation. Growth prospects are tied to the PELEUS platform and therapies for resistant solid tumors.

Achilles Therapeutics plc - ACHL Company Cash Balance (period 07/04/2022 - 03/29/2025)

Financial and market metric breakdowns for Achilles Therapeutics (ACHL)

- stock value and consensus price forecast:
Analysis of all company metrics:ACHL Achilles Therapeutics
Brand item of Achilles Tx

For Achilles Therapeutics (ACHL), as a developer of cell therapies with no current revenue, liquidity levels determine the survival horizon until product commercialization. This indicator measures the total cash and cash equivalents available for operational funding. By analyzing cash on hand, an investor assesses the burn rate. The trend of this metric reflects the efficiency of resource management in the absence of profit. The decline in balances confirms planned expenditures on clinical trials.